In Kenneth Frazier's first financial call as CEO, the exec withdrew Merck's long-term earnings guidance, citing healthcare reform costs, European pricing pressure and a late-stage pipeline setback.

In an acquisition said by both US-based companies to be highly complementary, Azurity Pharmaceuticals has taken control of Slayback Pharma for an undisclosed fee.

Ahead of the Global Generics & Biosimilars Awards, which are this year being held on Wednesday 25 October at the Hotel Porta Fira in Barcelona, we reveal our final shortlist of entrants across all 14 categories.